115 related articles for article (PubMed ID: 17015901)
21. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
[TBL] [Abstract][Full Text] [Related]
22. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
Rogers BE; Bigott HM; McCarthy DW; Della Manna D; Kim J; Sharp TL; Welch MJ
Bioconjug Chem; 2003; 14(4):756-63. PubMed ID: 12862428
[TBL] [Abstract][Full Text] [Related]
23. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
[TBL] [Abstract][Full Text] [Related]
24. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation.
Rossin R; Pan D; Qi K; Turner JL; Sun X; Wooley KL; Welch MJ
J Nucl Med; 2005 Jul; 46(7):1210-8. PubMed ID: 16000291
[TBL] [Abstract][Full Text] [Related]
25. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).
Biddlecombe GB; Rogers BE; de Visser M; Parry JJ; de Jong M; Erion JL; Lewis JS
Bioconjug Chem; 2007; 18(3):724-30. PubMed ID: 17378600
[TBL] [Abstract][Full Text] [Related]
26. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
[TBL] [Abstract][Full Text] [Related]
27. PET imaging of CCND1 mRNA in human MCF7 estrogen receptor positive breast cancer xenografts with oncogene-specific [64Cu]chelator-peptide nucleic acid-IGF1 analog radiohybridization probes.
Tian X; Aruva MR; Zhang K; Shanthly N; Cardi CA; Thakur ML; Wickstrom E
J Nucl Med; 2007 Oct; 48(10):1699-707. PubMed ID: 17909257
[TBL] [Abstract][Full Text] [Related]
28. MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts.
Yang H; Berger F; Tran C; Gambhir SS; Sawyers CL
Prostate; 2003 Apr; 55(1):39-47. PubMed ID: 12640659
[TBL] [Abstract][Full Text] [Related]
29. PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels.
Lövqvist A; Humm JL; Sheikh A; Finn RD; Koziorowski J; Ruan S; Pentlow KS; Jungbluth A; Welt S; Lee FT; Brechbiel MW; Larson SM
J Nucl Med; 2001 Aug; 42(8):1281-7. PubMed ID: 11483692
[TBL] [Abstract][Full Text] [Related]
30. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models.
Zheng QH; Gardner TA; Raikwar S; Kao C; Stone KL; Martinez TD; Mock BH; Fei X; Wang JQ; Hutchins GD
Bioorg Med Chem; 2004 Jun; 12(11):2887-93. PubMed ID: 15142549
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC).
Henriksen G; Herz M; Hauser A; Schwaiger M; Wester HJ
Nucl Med Biol; 2004 Oct; 31(7):851-8. PubMed ID: 15464386
[TBL] [Abstract][Full Text] [Related]
32. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
33. 64Cu-Labeled triphenylphosphonium and triphenylarsonium cations as highly tumor-selective imaging agents.
Wang J; Yang CT; Kim YS; Sreerama SG; Cao Q; Li ZB; He Z; Chen X; Liu S
J Med Chem; 2007 Oct; 50(21):5057-69. PubMed ID: 17867662
[TBL] [Abstract][Full Text] [Related]
34. High tumor uptake of (64)Cu: implications for molecular imaging of tumor characteristics with copper-based PET tracers.
Jørgensen JT; Persson M; Madsen J; Kjær A
Nucl Med Biol; 2013 Apr; 40(3):345-50. PubMed ID: 23394821
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Traumatic Brain Injury by Increased 64Cu Uptake on 64CuCl2 PET/CT.
Peng F; Muzik O; Gatson J; Kernie SG; Diaz-Arrastia R
J Nucl Med; 2015 Aug; 56(8):1252-7. PubMed ID: 26112025
[TBL] [Abstract][Full Text] [Related]
36. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.
Hoffman TJ; Gali H; Smith CJ; Sieckman GL; Hayes DL; Owen NK; Volkert WA
J Nucl Med; 2003 May; 44(5):823-31. PubMed ID: 12732685
[TBL] [Abstract][Full Text] [Related]
37. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
38. Choline PET for monitoring early tumor response to photodynamic therapy.
Fei B; Wang H; Wu C; Chiu SM
J Nucl Med; 2010 Jan; 51(1):130-8. PubMed ID: 20008981
[TBL] [Abstract][Full Text] [Related]
39. Distribution of radioiodinated estramustine binding protein antibody in mice with DU-145 prostate cancer xenograft.
Ståhlberg K; Kairemo K; Karonen SL; Taari K; Rannikko S
Anticancer Res; 2007; 27(4B):2275-8. PubMed ID: 17695514
[TBL] [Abstract][Full Text] [Related]
40. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
